The FDA has determined that the phase 3 SIERRA trial conducted by Actinium Pharmaceuticals is not adequate to support a BLA filing for Iomab-B to treat patients with active relapsed or refractory acute myeloid leukemia, the company recently announced.
Source: Drug Industry Daily